

Supplementary Table I. Clinical features of the antisynthetase patients taking either azathioprine (AZA), methotrexate (MTX) or both at any given point in their evolution.

	AZA (n=63)	MTX (n=26)	AZA and MTX [#] (n=26)	Total (n=115)
<i>Type of autoantibody</i>				
Anti-Jo1	70% (44)*	100% (26)**	77% (20)	78% (90)
Anti-PL7	10% (6)	0% (0)	8% (2)	7% (8)
Anti-PL12	16% (10)	0% (0)*	15% (4)	12% (14)
Anti-EJ	3% (2)	0% (0)	0% (0)	2% (2)
Anti-OJ	2% (1)	0% (0)	0% (0)	1% (1)
Age of onset	47.8 (13.3)	45.5 (11.9)	42.5 (11.9)	46.1 (12.8)
Time of follow-up (years)	4.1 (3.0)	4.9 (3.8)	4.9 (4.0)	4.4 (3.4)
Number of visits	10.3 (6.9)	8.7 (6.6)	10.5 (7.7)	10.0 (7.0)
Female sex	75% (47)	81% (21)	85% (22)	78% (90)
<i>Race</i>				
White	54% (34)	85% (22)**	46% (12)	59% (68)
Black	40% (25)	12% (3)*	35% (9)	32% (37)
Other races	6% (4)	4% (1)	19% (5)*	9% (10)
Mortality	5% (3)	0% (0)	12% (3)	5% (6)
Proximal weakness	86% (54)	85% (22)	92% (23)	87% (99)
<i>Strength</i>				
Mean strength	9.3 (0.8)*	9.0 (1.4)	8.8 (1.5)	9.1 (1.1)
Minimum strength	8.8 (1.2)*	8.2 (2.1)	7.9 (1.8)*	8.4 (1.6)
<i>Creatine kinase (CK)</i>				
Median CK	185 (99-630)*	283 (148-658)	428 (157-1164)*	260 (122-826)
Maximum CK	896 (254-3360)*	1412 (647-4144)	2508 (473-7904)	1331 (301-5000)
Interstitial lung disease	92% (58)**	62% (16)**	77% (20)	82% (94)
<i>FVC</i>				
Mean FVC	64.4 (20.0)**	86.7 (18.9)***	67.3 (15.9)	70.1 (20.9)
Minimum FVC	55.4 (21.4)***	80.7 (20.3)***	60.6 (18.9)	62.4 (22.9)
<i>Treatments</i>				
Corticosteroids	97% (61)	92% (24)	100% (26)	97% (111)
Mycophenolate	32% (20)	23% (6)	42% (11)	32% (37)
IVIG	32% (20)	31% (8)	50% (13)	36% (41)
Rituximab	25% (16)	31% (8)	27% (7)	27% (31)

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.[#]Methotrexate and azathioprine were not necessarily administered concomitantly.Each one of the treatment groups was compared to the rest of the patients. Dichotomous variables were shown as % (n) and compared using the chi-squared or Fisher's exact tests while continuous variables were reported as mean (SD) and compared using Student's *t*-test. The CK, a positively skewed variable, was presented as median (Q1-Q3) and compared using Wilcoxon rank-sum test.